Bcwp
1 known investors
BCWorld Pharm is a South Korean pharmaceutical company specializing in DDS (drug delivery system) technology, developing and manufacturing injectable and other prescription drugs. Its products address areas such as chemotherapy-related nausea, intravenous nutrition, and local anesthesia support.
Also known as BCWorld Pharm Co., Ltd. Β· BCWP Β· λΉμ¨μλμ μ½
Investors Β· 1
Company profile
researched Aug 2026BCWorld Pharm Co., Ltd. (Korean: λΉμ¨μλμ μ½; also referenced as BCWP) is a South Korean pharmaceutical company that develops, manufactures and markets prescription medicines, with a stated focus on formulation and process development for generic drugs. Its formulation capabilities span immediate- and controlled-release products, fast-dissolving drug delivery systems, gastro-retentive systems and depot formulations, and the group is described as having particular expertise in long-acting injectables and orally disintegrating tablets.
Marketed products highlighted by the company include Gratril injection 1ml, a clear ampoule injectable indicated for nausea and vomiting associated with chemotherapy, radiotherapy and surgery; Multipoten 9 injection, a vial-based product supplying trace elements during intravenous nutrition; and Malinda injection, used to increase the penetration of subcutaneous and intramuscular injections and local anesthetics and to promote reabsorption of excess fluid and blood in tissue. The company also issues regular regulatory notices on approval-condition changes for products containing ingredients such as pethidine, meropenem, valproic acid, sugammadex, codeine, fentanyl citrate sublingual tablets, rifampicin and fluoroquinolones. Recent additions to the portfolio include Ambaro ODT, positioned in the circulatory/cardiovascular area, and a P-CAB class gastrointestinal disease treatment.
BCWorld Pharm is the parent of BCWorld Healthcare Co., Ltd. (BCWH), founded in 2017, which operates what is described as the first MFDS-approved carbapenem-dedicated manufacturing facility in Korea and supplies antibiotics to the domestic market. BCWH also pursues diversification into medical devices, digital therapeutics and customized health functional foods.
Business model
The company develops, manufactures and sells prescription pharmaceuticals β notably injectables and orally disintegrating tablets β in Korea, using in-house formulation and process development capabilities; through its subsidiary BCWorld Healthcare it manufactures and supplies antibiotics and has begun in-licensing and distributing third-party medical devices for the Korean market.
Revenue derives from sales of prescription drug products, including generics and specialty injectables, and from distribution rights for licensed products in South Korea.
Traction
The company reports a marketed portfolio of injectable and oral prescription products, a first-quarter 2026 result characterized by operating profit growth, and a subsidiary operating Korea's first MFDS-approved carbapenem-dedicated plant. A third-party database associates roughly 250-500 employees with the company.
Latest developments
In 2026 the company announced the launch of Ambaro ODT in the circulatory/cardiovascular field, a P-CAB class gastrointestinal treatment, first-quarter results described as a solid start with operating profit growth, a 20th-anniversary commemorative ceremony in June 2026, a program with pharmacy students, and a site visit by Yeoju Mayor Lee Chung-woo. It also issued a series of regulatory notices on approval-condition changes for several drug ingredients.
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned as a technology- and formulation-driven Korean pharmaceutical company supplying quality generics and specialty injectables, with its subsidiary described as a leading supplier of carbapenem antibiotics in the Korean domestic market.
Differentiation is presented as cutting-edge formulation technology across immediate/controlled release, fast-dissolving DDS, GRS and depot forms, long-acting injectable and orally disintegrating tablet expertise, and dedicated carbapenem manufacturing capacity within the group.
Technology
Core technology centers on drug delivery systems and formulation science, including immediate-release and controlled-release forms, fast-dissolving DDS, gastro-retentive systems (GRS), depot formulations, long-acting injectables and orally disintegrating tablets. Manufacturing includes a carbapenem-dedicated facility approved by Korea's Ministry of Food and Drug Safety, operated by subsidiary BCWorld Healthcare.
Go-to-market
Products are commercialized directly to the Korean prescription market, supplemented by exclusive in-licensing and distribution agreements with overseas developers, and by recruitment and outreach programs including engagement with pharmacy students.
Hospitals, prescribers and pain-management physicians in South Korea, with product lines addressing oncology supportive care, intravenous nutrition, anesthesia support and antibiotics.
Geography
Headquartered in South Korea, with an address at 78, Gaepo-ro 22-gil, Gangnam-gu, Seoul, and operations associated with Gyeonggi-do; a directory listing records ten facilities in one country. The group states an intention to expand antibiotic supply beyond the domestic market.
History
Directory and database listings give 1980 as the company's founding year, while the company held a 20th-anniversary ceremony in June 2026. Subsidiary BCWorld Healthcare Co., Ltd. was founded in 2017 and built a carbapenem-dedicated manufacturing facility in Korea. In June 2023, BCWorld Healthcare signed an exclusive South Korean distribution agreement with U.S. medical device developer ReGelTec for the HYDRAFIL system, which included an equity investment in ReGelTec β described by BCWH as its first investment in a private company and its first step into medical devices.
Risks & controversies
Publicly visible operational matters include repeated regulatory notices of changes to approval conditions for marketed products containing ingredients such as pethidine, meropenem, valproic acid, sugammadex, codeine, fentanyl citrate and fluoroquinolones. The HYDRAFIL system is an investigational device pending Korean regulatory approval, so related revenue depends on MFDS clearance following a company-funded clinical study.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 7
launches, deals, and filingsSubsidiary BCWorld Healthcare Co., Ltd. obtained exclusive rights to distribute ReGelTec's HYDRAFIL hydrogel system for chronic low back pain due to degenerative disc disease in South Korea. The agreement included an equity investment by BCWH in ReGelTec and BCWH funding of a Korean clinical study to support MFDS approval, with the trial expected to begin in 2024.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- Bcwpbcwp.co.kr Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Bcwp do?
- BCWorld Pharm is a South Korean pharmaceutical maker of generics and injectables built on drug delivery system formulation technology.
- Who are Bcwp's investors?
- Bcwp's investors include Atinum Investment Co. Ltd..